London-based BC Partners together with Toronto-based Canada Pension Plan Investment Board (CPP Investments), via its wholly owned subsidiary CPP Investment Board Europe S.a.r.l., have agreed to jointly acquire Plochingen, Germany-based CeramTec GmbH.
BC Partners and CPP Investments to Acquire CeramTec
1 min read Premium comments
Secondary#ceramtec#bcpartners#cppinvestments
CPP Investments is providing approximately €800 million ($947.8 million USD) for a 50% stake in the business. Once the transaction is complete, CPP Investments and BC Partners Fund XI will jointly own CeramTec.
CeramTec is one of the world’s leading manufacturers of advanced ceramics for medical implants and customized industrial solutions and services customers out of 21 production sites across 11 countries.
CeramTec’s ceramic implant components are routinely used in orthopedics, dentistry, and veterinary medicine and are, in the company’s words, “highly biocompatible, extremely wear resistant and durable.” CeramTec is well known in the orthopedics industry for its pink BIOLOX® delta ceramics which are used for hip implants. CeramTec’s ceramics are also used in medical equipment, including surgical medical equipment and x-ray and MRI machinery.
OTW spoke with CPP Investments Managing Director, Head of Europe, Direct Private Equity Hafiz Lalani about the company’s decision to acquire CeramTec. Lalani told OTW, “CeramTec was a deliberate, targeted investment for us—they serve essential consumer/patient needs and their solutions significantly improve the quality of life for millions of people globally.”
Lalani continued, “As a business it already meets our criteria of scale and profitability, and we see an opportunity to leverage our experience, network and global reach to build an even larger, broader and stronger business.”
Lalani also discussed the company’s goals for the remainder of the year. “Going forward, we expect the company will continue on its strong growth path—continued expansion into adjacencies organically and through acquisition. We also support strong investment in R&D [research and development] which will improve patient outcomes even more.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.